Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (1976)	1/13/2006 2:16:11 PM
From: Ron	Respond to of 7944

AVII volume surge on ebola news. --- AVI BioPharma Inc. reported in a peer-reviewed journal that one of its drug technologies is proving effective in combating the deadly Ebola virus. AVI (Nasdaq: AVI - News) collaborated with the U.S. Army Medical Research Institute of Infectious Diseases to test the Portland company's Neugene antisense technology. The research showed that 75 percent of monkeys given an Ebola-specific Neugene agent were protected from a lethal exposure to the virus. Following the announcement, AVI shares hit a 52-week high of $5.18 Friday.